Security and Privacy Issues in Deep Learning: A Brief Review

2020 ◽  
Vol 1 (5) ◽  
Author(s):  
Trung Ha ◽  
Tran Khanh Dang ◽  
Hieu Le ◽  
Tuan Anh Truong
2019 ◽  
Vol 7 (5) ◽  
pp. 367-370
Author(s):  
Richa Verma ◽  
Shalini Chandra

Author(s):  
Martin Victor K ◽  
J. Immanuel Johnraja ◽  
Getzi Jeba Leelipushpam ◽  
J. Jebaveerasingh Jebadurai ◽  
I. Bildass Santhosam

2021 ◽  
Vol 135 (20) ◽  
pp. 2357-2376
Author(s):  
Wei Yan Ng ◽  
Shihao Zhang ◽  
Zhaoran Wang ◽  
Charles Jit Teng Ong ◽  
Dinesh V. Gunasekeran ◽  
...  

Abstract Ophthalmology has been one of the early adopters of artificial intelligence (AI) within the medical field. Deep learning (DL), in particular, has garnered significant attention due to the availability of large amounts of data and digitized ocular images. Currently, AI in Ophthalmology is mainly focused on improving disease classification and supporting decision-making when treating ophthalmic diseases such as diabetic retinopathy, age-related macular degeneration (AMD), glaucoma and retinopathy of prematurity (ROP). However, most of the DL systems (DLSs) developed thus far remain in the research stage and only a handful are able to achieve clinical translation. This phenomenon is due to a combination of factors including concerns over security and privacy, poor generalizability, trust and explainability issues, unfavorable end-user perceptions and uncertain economic value. Overcoming this challenge would require a combination approach. Firstly, emerging techniques such as federated learning (FL), generative adversarial networks (GANs), autonomous AI and blockchain will be playing an increasingly critical role to enhance privacy, collaboration and DLS performance. Next, compliance to reporting and regulatory guidelines, such as CONSORT-AI and STARD-AI, will be required to in order to improve transparency, minimize abuse and ensure reproducibility. Thirdly, frameworks will be required to obtain patient consent, perform ethical assessment and evaluate end-user perception. Lastly, proper health economic assessment (HEA) must be performed to provide financial visibility during the early phases of DLS development. This is necessary to manage resources prudently and guide the development of DLS.


2019 ◽  
Vol 8 (1) ◽  
pp. 95-99 ◽  
Author(s):  
Dalton A. Hahn ◽  
Arslan Munir ◽  
Saraju P. Mohanty

Sign in / Sign up

Export Citation Format

Share Document